As labs implement TMB workflows in-house, studies are showing that its is possible to validate assays with cutoff points remaining stable across complex clinical cohorts and in different drug contexts.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
